Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
146 hedge funds and large institutions have $1.1B invested in Insys Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 63 increasing their positions, 41 reducing their positions, and 19 closing their positions.
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
54% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 41
31% more capital invested
Capital invested by funds: $841M → $1.1B (+$257M)
10% more funds holding
Funds holding: 133 → 146 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
39% less call options, than puts
Call options by funds: $44.3M | Put options by funds: $72.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$27.2M |
| 2 |
BTP
Bloom Tree Partners
New York
|
+$21.9M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$15.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$11.2M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$8.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$13.3M |
| 3 |
Millennium Management
New York
|
-$9.97M |
| 4 |
TA
Teachers Advisors
New York
|
-$5.92M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$5.85M |
INSY Hedge Fund Activity: Q2 2015 in Review
146 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2015, worth a combined $1.1B — up 31% from $841M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new INSY positions and 19 closed out — a net gain of 13 holders — while 63 added to existing stakes and 41 trimmed.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $27.2M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $16M sold.
- 146 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2015, up from 133 in Q1 2015.
- Funds reported $1.1B of Insys Therapeutics, Inc. stock for Q2 2015, up 31% quarter-over-quarter.
- 32 funds opened new Insys Therapeutics, Inc. positions in Q2 2015 and 19 closed out, a net change of +13 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2015 was Scopia Capital Management, an estimated $27.2M added.
- The largest Insys Therapeutics, Inc. seller in Q2 2015 was Adage Capital Partners, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2015.